INKON Life Technology Co (300143) Fair Value & Analysis

Healthcare · CN · Market cap 6.8B CNY

Analysis

INKON Life Technology Co (300143) currently trades at ¥6.91, while our model-based Fair Value estimate is ¥2.67 — implying the stock looks roughly 61.4% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

INKON Life Technology Co., Ltd. focuses on building an ecosystem platform for providing medical services for tumors in China and internationally. It provides medical devices solutions for radiotherapy, life support, image enhancement, and chronic disease treatment; and oncology medical services, as well as equipment for cancer prevention, diagnosis, treatment, and rehabilitation. The company was formerly known as Starmap Medicine and Technology Co., Ltd. and changed its name to INKON Life Technology Co., Ltd. in July 2019. INKON Life Technology Co., Ltd. was founded in 1998 and is headquartered in Qingdao, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.